David M. Livermore
Impact in
- Molecular Medicine top 0.01%
- Antibiotic Resistance in Bacteria
- Applied Microbiology and Biotechnology top 0.01%
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 338
-
- Antibiotic Use and Resistance 73
- Co-authors
- Neil Woodford (125 shared papers)Shazad Mushtaq (78 shared papers)Jane F. Turton (19 shared papers)Marina Warner (34 shared papers)Timothy Rutland Walsh (4 shared papers)Michel Doumith (36 shared papers)Lucinda M. C. Hall (22 shared papers)Meghan Warner (29 shared papers)
- Journals
- Journal of Antimicrobial Chemotherapy (199 papers)Antimicrobial Agents and Chemotherapy (60 papers)International Journal of Antimicrobial Agents (32 papers)Clinical Microbiology and Infection (18 papers)Journal of Medical Microbiology (13 papers)
- Partner nations
- United KingdomUnited StatesNepal
In The Last Decade
David M. Livermore
452 papers receiving 38.6k citations
David M. Livermore's Hit Papers
Peers
Comparison fields: 5 of 186
- Molecular Medicine 28.6k
- Applied Microbiology and Biotechnology 5.7k
- Endocrinology 8.7k
- Clinical Biochemistry 4.4k
- Pharmacology 8.7k
Countries citing papers authored by David M. Livermore
This map shows the geographic impact of David M. Livermore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Livermore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Livermore more than expected).
Fields of papers citing papers by David M. Livermore
This network shows the impact of papers produced by David M. Livermore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Livermore. The network helps show where David M. Livermore may publish in the future.
Co-authors
The 25 scholars most cited alongside David M. Livermore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 458 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Hit paper breakdown → | 2010 | 2435 |
| 2 | beta-Lactamases in laboratory and clinical resistance Hit paper breakdown → | 1995 | 1447 |
| 3 | Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases Hit paper breakdown → | 2013 | 1374 |
| 4 | Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study Hit paper breakdown → | 2011 | 1051 |
| 5 | Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe Hit paper breakdown → | 2012 | 752 |
| 6 | Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance Hit paper breakdown → | 2011 | 727 |
| 7 | 2006 | 656 | |
| 8 | Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study Hit paper breakdown → | 2016 | 579 |
| 9 | The emerging NDM carbapenemases Hit paper breakdown → | 2011 | 559 |
| 10 | 2006 | 550 | |
| 11 | European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia Hit paper breakdown → | 2013 | 505 |
| 12 | Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection Hit paper breakdown → | 2019 | 487 |
| 13 | 2003 | 456 | |
| 14 | 2004 | 441 | |
| 15 | 2001 | 417 | |
| 16 | 2006 | 416 | |
| 17 | 2004 | 397 | |
| 18 | 2000 | 359 | |
| 19 | 2009 | 355 | |
| 20 | 1994 | 354 |
About David M. Livermore
David M. Livermore is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Pharmacology, Endocrinology and Clinical Biochemistry, having authored 458 papers that have together received 41.0k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (338 papers), Antibiotics Pharmacokinetics and Efficacy (120 papers), Antibiotic Use and Resistance (73 papers), Antimicrobial Resistance in Staphylococcus (59 papers), Bacterial Identification and Susceptibility Testing (56 papers), Pneumonia and Respiratory Infections (53 papers), Pharmaceutical and Antibiotic Environmental Impacts (51 papers) and Bacterial biofilms and quorum sensing (43 papers). The work is most often cited by research in Molecular Medicine (28.6k citations), Applied Microbiology and Biotechnology (5.7k citations), Endocrinology (8.7k citations), Clinical Biochemistry (4.4k citations) and Pharmacology (8.7k citations). David M. Livermore has collaborated with scholars based in United Kingdom, United States and Nepal. Frequent co-authors include Neil Woodford, Shazad Mushtaq, Jane F. Turton, Marina Warner, Timothy Rutland Walsh, Michel Doumith, Lucinda M. C. Hall, Meghan Warner, Mark Alexander Toleman and Janis L. Weeks. Their work appears in journals such as Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, International Journal of Antimicrobial Agents, Clinical Microbiology and Infection and Journal of Medical Microbiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.